2025-10-21T18:56:10-05:00 2024-12-31 954046751 KATZ CASSIDY AN ACCOUNTANCY CORPORATION 11400 W OLYMPIC BLVD SUITE 1050 LOS ANGELES CA 90064 990 2024-01-01 311763110 FOUNDATION FOR PRADER-WILLI RESEARCH INC FOUN 8883225487 440 N BARRANCA AVE 3620 COVINA CA 91723 SUSAN HEDSTROM EXECUTIVE DIRECTOR 8883225487 2025-10-20 1 0 NEAL KATZ P01053915 3104776300 2025-10-17 2024 2025-03-06 01:10:19Z SUSAN HEDSTROM 440 N BARRANCA AVE 3620 COVINA CA 91723 10397765 0 X WWW.FPWR.ORG X 2001 NY SUPPORTS RESEARCH TO ADVANCE THE UNDERSTANDING AND TREATMENT OF PRADER-WILLI SYNDROME. 11 11 13 50 0 0 5653599 5412703 229189 186058 294425 495956 358367 78943 6535580 6173660 3877623 3413154 0 0 1127088 1181179 0 0 362394 1347431 1468006 6352142 6062339 183438 111321 9519457 8871895 4227228 3480573 5292229 5391322 TO ELIMINATE THE CHALLENGES OF PRADER WILLI SYNDROME THROUGH THE ADVANCEMENT OF RESEARCH AND THERAPEUTIC DEVELOPMENT. 0 0 5303789 3413154 186058 THROUGH THE IMPLEMENTATION OF TRANSLATIONAL RESEARCH PROGRAMS, THE MANAGEMENT OF A WORLD-CLASS GRANTS PROGRAM, AND THE DEVELOPMENT OF PRADER WILLI SYNDROME (PWS) RESEARCH TOOLS, THE FOUNDATION FOR PRADER-WILLI RESEARCH (FPWR) ADVANCES RESEARCH IN ORDER TO DEVELOP NEW TREATMENTS FOR PWS AND IMPROVE THE HEALTH AND WELL-BEING OF THOSE WITH PWS. UNDER THE GUIDANCE OF OUR SCIENTIFIC ADVISORY BOARD THROUGH A CAREFULLY MANAGED GRANTS PROCESS, FPWR SELECTS RESEARCH PROJECTS BASED ON THE COLLABORATIVE INPUT OF RESEARCHERS AND PARENTS, CHOOSING PROJECTS THAT ARE BOTH SCIENTIFICALLY MERITORIOUS AND HIGHLY RELEVANT FOR INDIVIDUALS WITH PWS AND THEIR FAMILIES. 5303789 1 1 0 0 0 0 0 0 0 0 1 0 1 0 0 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 X 0 0 13 1 0 0 0 0 0 1 1 0 0 0 0 X 11 11 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS NH NJ NY NC ND OK OR PA SC TN UT VA WV WI X X SPRCHRGR 3106256262 8605 SANTA MONICA BLVD WEST HOLLYWOOD CA 90069 PAUL WISSMAN CHAIRPERSON 1.00 X X 0 0 0 JUSTIN NELSON VICE CHAIRPERSON 0.50 X X 0 0 0 AMBER ROBERSON SECRETARY 0.50 X X 0 0 0 BRIAN CARUCCI TREASURER 0.50 X X 0 0 0 ANNAMARIE HUTTUNEN DIRECTOR 0.50 X 0 0 0 KARINE KABUNDI DIRECTOR 0.50 X 0 0 0 KRISTIN WHITE DIRECTOR 0.50 X 0 0 0 MARK JOSEPH DIRECTOR 0.50 X 0 0 0 MATT BLICKLEY DIRECTOR 0.50 X 0 0 0 RENEE SNYDER DIRECTOR 0.50 X 0 0 0 SCOTT ARANT DIRECTOR 0.50 X 0 0 0 SUSAN HEDSTROM EXECUTIVE DIRECTOR 35.00 X 132351 0 0 THERESA STRONG DIRECTOR OF RESEARCH PROGR 40.00 X 173430 0 0 305781 0 0 5 0 1 0 0 883542 4529161 5412703 CONFERENCE REVENUE 900099 186058 186058 186058 459894 459894 4104035 4067973 36062 36062 36062 235075 883542 156132 78943 78943 6173660 186058 0 574899 2597065 2597065 816089 816089 132351 94448 11763 26140 952360 679618 84644 188098 12555 3564 926 8065 83913 61711 4635 17567 2475 2475 82596 82596 543453 435380 88667 19406 1240 680 560 53801 47651 6150 74384 60791 5053 8540 2047 2047 29193 20131 9062 CATERING 244413 225732 0 18681 RESEARCH 209154 209154 DUES & SUBSCRIPTIONS 77658 31469 40289 5900 BANK FEES 60192 102 55920 4170 87400 17729 10554 59117 6062339 5303789 396156 362394 32336 0 8885256 7637715 164138 618795 55784 109268 13561 8711 3932 4850 28011 1267 350000 500000 9519457 8871895 694953 201489 3532275 3279084 4227228 3480573 X 5292229 5391322 5292229 5391322 9519457 8871895 X 111321 -50137 37909 X X 0 1 X 1 0 X 3495770 3612120 4654934 5653599 5412703 22829126 3495770 3612120 4654934 5653599 5412703 22829126 7316333 15512793 26556 1677 83302 219505 459894 790934 114368 349960 78943 543271 116 8407 8523 24171854 1143450 0.64180 0.69970 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2022 AMOUNT: $ 116. 2023 AMOUNT: $ 8,407. 2024 AMOUNT: $ 0. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 13561 8711 4850 4850 CONVERTIBLE NOTE-PALOBIOFARMA 100000 C PREFERRED SERIES A-LIPIDIO PHARMACEUTICALS 100000 C PREFERRED SERIES B-AARDVARK THERAPEUTICS 150000 C PREFERRED SERIES C-AARDVARK THERAPEUTICS 150000 C 500000 X 6088627 -50136 -34897 -85033 6173660 0 6173660 5989534 -72390 -72390 6061924 415 415 6062339 PART X, LINE 2: THE FOUNDATION RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE FOUNDATION HAD NO UNCERTAIN POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. THE FOUNDATION IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR PERIODS PRIOR TO 2020. PART XI, LINE 2D - OTHER ADJUSTMENTS: DIRECT BENEFITS TO DONORS -191,029. DIRECT FUNDRAISING EXPENSES 156,132. PART XII, LINE 2D - OTHER ADJUSTMENTS: DIRECT BENEFITS TO DONORS -191,029. RETURN OF PRIOR YEAR GRANTS -37,493. DIRECT FUNDRAISING EXPENSES 156,132. PART XII, LINE 4B - OTHER ADJUSTMENTS: DEPRECIATION EXPENSE 415. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS IN REGION FOR RESEARCH 610093 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS IN REGION FOR RESEARCH 79488 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTS TO RECIPIENTS IN REGION FOR RESEARCH 126508 0 0 0 0 0 0 816089 0 816089 EAST ASIA AND THE PACIFIC RESEARCH 79488 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 33000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 172989 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM RESEARCH 108000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 136758 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) RESEARCH 159346 WIRE TRANSFER 0 NORTH AMERICA RESEARCH 126508 WIRE TRANSFER 0 7 0 0 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION (FPWR) HAS A PROFESSIONALY MANAGED GRANT PROCESS THAT ELECTS PROJECTS BASED ON THE COLLABORATIVE INPUT OF BOTH SCIENTISTS AND PARENTS. FPWR CHOOSES PROJECTS THAT ARE BOTH SCIENTIFICALLY SOUND AND HIGHLY RELEVANT FOR INDIVIDUALS WITH PRADER-WILLI SYNDROME (PWS) AND THEIR FAMILIES. FPWR'S GRANT PROCESS IS MANAGED BY A SCIENTIFIC ADVISORY BOARD THAT HAS ESTABLISHED THE FOLLOWING OBJECTIVES: 1. STIMULATE RESEARCH THAT WILL ADDRESS THE CHALLENGES FACED BY THOSE WITH PWS. 2. SUPPORT RESEARCH THAT DIRECTLY DEVELOPS AND EVALUATES NEW THERAPEUTIC APPROACHES TO PWS. 3. SUPPORT INNOVATIVE RESEARCH THAT WILL LEAD TO SIGNIFICANT ADVANCES IN UNDERSTANDING PWS. 4. SUPPORT EARLY STUDIES THAT ALLOW INVESTIGATORS TO OBTAIN THE NECESSARY DATA TO SUPPORT FURTHER INVESTIGATION OF PWS. 5. INVOLVE PARENTS IN THE PROCESS OF IDENTIFYING RELEVANT AREAS OF RESARCH AND SELECTING THE MOST DESERVING RESEARCH PROPOSALS. TO REACH THESE OBJECTIVES, FPWR TARGETS THE FOLLOWING GROUPS FOR ALLOCATION OF RESEARCH GRANTS, ALL WITH THE GOAL OF BROADENING THE BASE OF RESEARCH DONE ON PWS: 1. NEW INVESTIGATORS TO HELP THEM ESTABLISH CAREERS IN PWS RESEARCH. 2. WELL ESTABLISHED NON-PWS INVESTIGATORS TO HELP THEM BRING EXPERTISE IN RELEVANT AREAS OF RESEARCH TO ADDRESS THE PROBLEMS ASSOCIATED WITH PWS. 3. ESTABLISHED PWS INVESTIGATORS TO HELP THEM INITIATE NEW LINES OF PWS RESEARCH. PART I, LINE 3: THE ORGANIZATION USES THE ACCRUAL METHOD OF ACCOUNTING TO ACCOUNT FOR ITS FOREIGN EXPENDITURES. ;LISTTOTAL 1425846 PARS FOR PEYTON 245325 117695 127630 3856 31675 3009 850 19410 IGGS FESTIVAL 245416 198466 46950 168 3000 33000 1074 19096 9 627876 567381 60495 6196 16921 17698 177 1118617 883542 235075 4024 40871 52930 19622 38683 156130 78945 1 EMORY UNIVERSITY 1599 CLIFTON ROAD 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 300000 0 RESEARCH SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE 3545 LINDELL BLVD 3RD FLOOR ST LOUIS MO 63103 430654872 501(C)(3) 222156 0 RESEARCH ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX NY 10461 830621846 501(C)(3) 162000 0 RESEARCH DUKE UNIVERSITY PO BOX 602651 CHARLOTTE NC 28260 560532129 501(C)(3) 162000 0 RESEARCH ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 501(C)(3) 162000 0 RESEARCH SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 10901 NORTH TORREY PINES RD LA JOLLA CA 92037 510197108 501(C)(3) 162000 0 RESEARCH UNIVERSITY OF NEBRASKA 151 PREM S PAL RESEARCH CENTER 2200 VINE ST LINCOLN NE 68583 470049123 501(C)(3) 162000 0 RESEARCH YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 162000 0 RESEARCH UNIVERSITY OF PITTSBURGH 3100 CATHEDRAL OF LEARNING PITTSBURGH PA 15260 251865744 501(C)(3) 161999 0 RESEARCH CARNEGIE MELLON UNIVERSITY 5000 FORBES AVE PITTSBURGH PA 15213 250969449 501(C)(3) 161998 0 RESEARCH UNIVERSITY OF CONNECTICUT HEALTH CENTER 263 FARMINGTON AVE FARMINGTON CT 06030 521725543 501(C)(3) 137700 0 RESEARCH DUKE UNIVERSITY 2200 W MAIN STREET STE 1000 DURHAM NC 27705 560532129 501(C)(3) 108000 0 RESEARCH TULANE UNIVERSITY 800 COMMERCE RD EAST SUITE 203 NEW ORLEANS LA 70123 720423889 501(C)(3) 95591 0 RESEARCH JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 510595110 501(C)(3) 86400 0 RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 18 BEE STREET MSC450 GRANTS CONTRACTS ACCOUNTING CHARLESTON SC 29425 576000722 501(C)(3) 86400 0 RESEARCH UNIVERSITY OF ALABAMA AT BIRMINGHAM 1600 7TH AVENUE SOUTH LOWDER 608 BIRMINGHAM AL 35235 636005396 501(C)(3) 83621 0 RESEARCH VANDERBILT UNIVERSITY 3841 GREEN HILLS VILLAGE DRIVE NASHVILLE TN 37215 620476822 501(C)(3) 75639 0 RESEARCH BUCKNELL UNIVERSITY DEPARTMENT OF PSYCHOLOGY LEWISBURG PA 17837 240772407 501(C)(3) 72984 0 RESEARCH COLUMBIA UNIVERSITY 615 W 131ST ST MAIL CODE 8749 NEW YORK NY 10027 135598093 501(C)(3) 27174 0 RESEARCH UNIVERSITY OF CONNECTICUT 438 WHITNEY ROAD EXTENSION UNIT 1133 STORRS CT 06269 521725543 501(C)(3) 5400 0 RESEARCH PART I, LINE 2: THE ORGANIZATION HAS PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS TO ENSURE THAT SUCH GRANTS ARE USED FOR INTENDED PURPOSES AND NOT OTHERWISE DIVERTED FROM THE INTENDED USE. GRANTEES ARE REQUIRED TO COMPLETE A REPORT OF THEIR EXPENDITURES AT THE END OF THE GRANT PERIOD, AND PROVIDE THE REPORT TO THE ORGANIZATION. ADDITIONAL INFORMATION ABOUT THE PURPOSES OF THE ORGANIZATION'S GRANTS AND SELECTION PROCESS IS INCLUDED BELOW. THE FOUNDATION FOR PRADER-WILLI RESEARCH (FPWR) IS DEDICATED TO SUPPORTING RESEARCH TO ADVANCE THE UNDERSTANDING AND TREATMENT OF PRADER-WILLI SYNDROME (PWS). WE INVITE APPLICATIONS FOR FUNDING ON AN ANNUAL OR SEMIANNUAL BASIS, IN RESPONSE TO A REQUEST FOR APPLICATIONS. FPWR ACCEPTS APPLICATIONS IN ALL AREAS OF RESEARCH RELEVANT TO PWS, BUT WE ARE PARTICULARLY INTERESTED IN SUPPORTING PROJECTS THAT WILL LEAD TO NEW INTERVENTIONS TO ALLEVIATE THE SYMPTONS ASSOCIATED WITH PWS. FPWR ACCEPTS APPLICATIONS FROM ACADEMIC, GOVERNMENT, NON-PROFIT, OR FOR-PROFIT RESEARCH ENTITIES. ACADEMIC RESEARCH APPLICANTS SHOULD HAVE A PRIMARY FACULTY APPOINTMENT AT THE LEVEL OF INSTRUCTOR OR HIGHER. THIS GRANT PROGRAM WILL BE USEFUL FOR JUNIOR FACULTY IN THE EARLY STAGES OF THEIR CAREERS, ESTABLISHED INVESTIGATORS IN OTHER AREAS OF RESEARCH WHO WISH TO ENTER THE FIELD OF PWS RESEARCH, OR INVESTIGATORS IN THE PWS FIELD WHO ARE SEEKING FUNDING TO SUPPORT PILOT STUDIES IN A NEW AREA OF PWS RESEARCH. FPWR SEEKS TO SUPPORT INNOVATIVE, HIGH-RISK/HIGH REWARD RESEARCH IN ITS EARLY STAGES. APPLICATIONS MEETING THE TECHNICAL REQUIREMENTS ARE REVIEWED BY SCIENTIFIC REVIEWERS, WHO HAVE EXPERTISE IN THE RESEARCH AREA, AS WELL AS AN ADVOCATE REVIEWER WHO EVALUATES THE RELEVANCE OF THE PROPOSED RESEARCH TO THE PWS COMMUNITY. FINAL FUNDING DECISIONS ARE BASED ON SCIENTIFIC MERIT, RELEVANCE TO PWS, AND THE SUITABILITY OF THE RESEARCH WITH RESPECT TO THE PROGRAMMATIC GOALS OF FPWR. X X X 0 0 0 0 0 0 0 0 0 THERESA STRONG DIRECTOR OF RESEARCH PROGR 173430 0 0 0 0 0 0 0 0 0 173430 0 0 0 FORM 990, PART V, LINE 2B: THE ORGANIZATION CONTRACTED WITH A PROFESSIONAL EMPLOYER ORGANIZATION (PEO) FOR SERVICES, INCLUDING BUT NOT LIMITED TO, PAYROLL, TIMEKEEPING, EMPLOYEE BENEFITS, HR ADMINISTRATION, AND WORKFORCE REGULATORY COMPLIANCE NEEDS. AS THE EMPLOYER OF RECORD FOR TAX PURPOSES, FORMS W-2 AND W-3 ARE ISSUED BY THE PEO AND FILED UNDER THE PEO'S FEDERAL EIN. IN THIS CO-EMPLOYMENT ARRANGEMENT, THE ORGANIZATION IS THE COMMON LAW EMPLOYER AND, ACCORDINGLY, COMPENSATION IS REPORTED ON FORM 990, PART VII, SECTION A AND PART IX, LINES 5-10. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION HAS ITS FORM 990 PREPARED BY AN OUTSIDE ACCOUNTING FIRM. IT IS REVIEWED BY THE EXECUTIVE DIRECTOR AND A COMPLETE COPY IS PROVIDED TO ALL MEMBERS OF THE GOVERNING BODY FOR THEIR REVIEW PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS AND THE GOVERNANCE COMMITTEE ARE RESPONSIBLE FOR DETERMING AND REVIEWING CONFLICTS OF INTEREST. ALL BOARD MEMBERS AND OFFICERS ARE REQUIRED TO SELF-DISCLOSE CONFLICTS AS THEY ARISE AS WELL AS ANNUALLY SIGN A DISCLOSURE FORM NOTING ANY POTENTIAL CONFLICTS OF INTEREST. SUCH PERSONS MAY MAKE A PRESENTATION AT THE GOVERNING BOARD OR COMMITTEE MEETING, BUT AFTER THE PRESENTATION, THEY MUST LEAVE DURING THE DISCUSSION OF, AND THE VOTE ON, THE TRANSACTION OR ARRANGEMENT. FORM 990, PART VI, SECTION B, LINE 15A THE PROCESS FOR DETERMINING THE COMPENSATION OF THE CEO INCLUDED THE USE OF COMPARABILITY DATA, REVIEW AND APPROVAL BY THE EXECUTIVE COMMITTE OF THE BOARD, AND CONTEMPORANEOUS DOCUMENTATION. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9: RETURN OF PRIOR YEAR GRANT EXPENSE 37,493. DEPRECIATION ADJUSTMENT 416. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND THE SELECTION OF AN INDEPENDENT ACCOUNTANT. THIS PROCESS DID NOT CHANGE FROM THE PRIOR YEAR.